ReviewNano convergence2020
High density lipoprotein mimicking nanoparticles for atherosclerosis.
Review in Nano convergence, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 55 citations in OpenAlex.
- Application of nanotherapy in cardiovascular diseases featuring novel pharmacological mechanisms and drug delivery strategies.Discover nano · 2026Review
- Artificial recombinant high-density protein nanocarriers for precision drug delivery.Chemical science · 2026Review
- Nanomedicine-based theranostics in atherosclerotic cardiovascular diseases.Journal of biomedical science · 2026Review
- Macrophage reprogramming through scavenger receptor-guided and cathepsin B-triggered nanodelivery: from intracellular mechanisms to translational applications.Frontiers in immunology · 2026Review
- Recent Advances in Nanodelivery Systems Based on Extracellular and Intracellular Reprogramming Strategies for Enhanced Therapy of Atherosclerosis.International journal of nanomedicine · 2026Review
- Inventive HDL Mimicking Nanoparticles: A Promising Frontier in Cardiovascular Disease Management.Cardiovascular toxicology · 2025Review
- Inventive HDL Mimicking Nanoparticles: A Promising Frontier in Cardiovascular Disease Management.Cardiovascular toxicology · 2025Review
- Recent Advances in Nanozymes for the Treatment of Atherosclerosis.International journal of nanomedicine · 2025Review
- Stimuli-responsive Nano/Biomaterials for Smart Drug Delivery in Cardiovascular Diseases: Promises, Challenges and Outlooks.Current medicinal chemistry · 2025Review
- Nano Delivery System for Atherosclerosis.Journal of functional biomaterials · 2024Review
- Synthetic high-density lipoprotein (sHDL): a bioinspired nanotherapeutics for managing periapical bone inflammation.International journal of oral science · 2024Article
- Nanoparticles as Drug Delivery Systems for the Targeted Treatment of Atherosclerosis.Molecules (Basel, Switzerland) · 2024Review
- Advances in Atherosclerosis Theranostics Harnessing Iron Oxide-Based Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Photodynamic Therapy for Atherosclerosis.International journal of molecular sciences · 2024Review
- Multifunctional nanoparticle-mediated combining therapy for human diseases.Signal transduction and targeted therapy · 2024Review
- Recent advances of self-assembled nanoparticles in the diagnosis and treatment of atherosclerosis.Theranostics · 2024Review
- Molecular imaging nanoprobes and their applications in atherosclerosis diagnosis.Theranostics · 2024Review
- Expression of recombinant human Apolipoprotein A-IBioresources and bioprocessing · 2023Article
- Methods for Radiolabelling Nanoparticles: PET Use (Part 2).Biomolecules · 2022Review
- Surface-modified nanotherapeutics targeting atherosclerosis.Biomaterials science · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Atherosclerosis is a major contributor to many cardiovascular events, including myocardial infarction, ischemic stroke, and peripheral arterial disease, making it the leading cause of death worldwide. High-density lipoproteins (HDL), also known as "good cholesterol", have been shown to demonstrate anti-atherosclerotic efficacy through the removal of cholesterol from foam cells in atherosclerotic plaques. Because of the excellent anti-atherosclerotic properties of HDL, in the past several years, there has been tremendous attention in designing HDL mimicking nanoparticles (NPs) of varying functions to image, target, and treat atherosclerosis. In this review, we are summarizing the recent progress in the development of HDL mimicking NPs and their applications for atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.